MEF2C

Across TCGA pan-cancer cohorts, MEF2C mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEF2C data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MEF2C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MEF2C expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where MEF2C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	1.000	0.149	.014	26	view →
UCEC	OS	Median	II,III,IV	0.678	1.000	.048	14	view →
LSCC	DFS	Median	All	0.880	0.731	.032	2	view →
PDAC	OS	Quartile	All	0.955	0.843	.027	2	view →
HNSC	DFS	Tertile	IV	0.884	0.606	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEF2C–CCRCC (DFS)

Open the CCRCC breakdown →